Clinical study - Sein métastatique HER2+

The main objectives of this study are as follows:;- Provide trastuzumab emtansine treatment as monotherapy or in combination with other therapeutic agents in patients with HER2-positive metastatic cancer already benefiting from trastuzumab emtansine treatment in other trials promoted by Roche/Genentech that we calls ÀparentÀ tests.;- Ensure continuity of treatment in patients in the control arm of study BO21976/TDM4450g who benefited from the treatment administered during the study.;Patients in the control arm of study BO21976/TDM4450g who discontinued treatment due to disease progression may be eligible to receive treatment with trastuzumab emtansine;- Collect safety and tolerability data relating to the long-term administration of trastuzumab emtansine treatment as monotherapy or in combination with other therapeutic agents.